JP7340458B2 - Ｈｐｖ＋悪性腫瘍を有する患者におけるｐｄｌ１とｔｇｆベータの遮断の組み合わせ - Google Patents

Ｈｐｖ＋悪性腫瘍を有する患者におけるｐｄｌ１とｔｇｆベータの遮断の組み合わせ Download PDF

Info

Publication number
JP7340458B2
JP7340458B2 JP2019561944A JP2019561944A JP7340458B2 JP 7340458 B2 JP7340458 B2 JP 7340458B2 JP 2019561944 A JP2019561944 A JP 2019561944A JP 2019561944 A JP2019561944 A JP 2019561944A JP 7340458 B2 JP7340458 B2 JP 7340458B2
Authority
JP
Japan
Prior art keywords
cancer
composition
hpv
patients
agents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019561944A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020519614A5 (https=
JP2020519614A (ja
Inventor
ワイ． シュトラウス、ジュリアス
エル． ガリー、ジェイムズ
エス． ヒンリクス、クリスチャン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Government of the United States of America
Original Assignee
Government of the United States of America
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Government of the United States of America filed Critical Government of the United States of America
Publication of JP2020519614A publication Critical patent/JP2020519614A/ja
Publication of JP2020519614A5 publication Critical patent/JP2020519614A5/ja
Application granted granted Critical
Publication of JP7340458B2 publication Critical patent/JP7340458B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2019561944A 2017-05-09 2018-05-08 Ｈｐｖ＋悪性腫瘍を有する患者におけるｐｄｌ１とｔｇｆベータの遮断の組み合わせ Active JP7340458B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762503405P 2017-05-09 2017-05-09
US62/503,405 2017-05-09
PCT/US2018/031501 WO2018208720A1 (en) 2017-05-09 2018-05-08 Combination pdl1 and tgf-beta blockade in patients with hpv+ malignancies

Publications (3)

Publication Number Publication Date
JP2020519614A JP2020519614A (ja) 2020-07-02
JP2020519614A5 JP2020519614A5 (https=) 2021-06-10
JP7340458B2 true JP7340458B2 (ja) 2023-09-07

Family

ID=62530530

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019561944A Active JP7340458B2 (ja) 2017-05-09 2018-05-08 Ｈｐｖ＋悪性腫瘍を有する患者におけるｐｄｌ１とｔｇｆベータの遮断の組み合わせ

Country Status (5)

Country Link
US (1) US11440963B2 (https=)
EP (1) EP3624895B1 (https=)
JP (1) JP7340458B2 (https=)
AU (1) AU2018266103B2 (https=)
WO (1) WO2018208720A1 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11583593B2 (en) 2016-01-14 2023-02-21 Synthis Therapeutics, Inc. Antibody-ALK5 inhibitor conjugates and their uses
AU2019301070B2 (en) 2018-07-09 2025-09-11 Precigen, Inc. Fusion constructs and methods of using thereof
WO2020013803A1 (en) * 2018-07-09 2020-01-16 Synthis, Llc Antibody-alk5 inhibitor conjugates and their uses
CN113226335B (zh) * 2018-12-06 2023-10-13 广东天科雅生物医药科技有限公司 靶向肿瘤抗原、TGF-β、和免疫检查点的组合型TCR-T细胞疗法
WO2021061437A1 (en) * 2019-09-12 2021-04-01 Sirnaomics, Inc. CO-DELIVERY OF TGF-β SIRNA AND PDL1 SIRNA TO TREAT CANCER
WO2021084124A1 (en) 2019-11-01 2021-05-06 Ares Trading S.A. COMBINED INHIBITION OF PD-1, TGFβ AND ATM TOGETHER WITH RADIOTHERAPY FOR THE TREATMENT OF CANCER
IL292758A (en) 2019-11-05 2022-07-01 Merck Patent Gmbh Combined inhibition of pd-1, tgfb and tigit for the treatment of cancer
TW202128763A (zh) * 2019-11-12 2021-08-01 大陸商江蘇恆瑞醫藥股份有限公司 含有ＴＧＦ－β受體的融合蛋白及其醫藥用途
JP7730817B6 (ja) 2019-12-20 2025-09-26 アレス トレーディング ソシエテ アノニム ＩｇＧ：ＴＧＦβＲＩＩ融合タンパク質組成物
EP3838260A1 (en) 2019-12-20 2021-06-23 Ares Trading S.A. Igg:tgf rii fusion protein composition
WO2021209458A1 (en) 2020-04-14 2021-10-21 Ares Trading S.A. Combination treatment of cancer
CA3175490A1 (en) * 2020-04-14 2021-10-21 Glaxosmithkline Intellectual Property Limited Combination treatment for cancer based upon an icos antibody and a pd-l1 antibody tgf-beta-receptor fusion protein
WO2022011256A1 (en) 2020-07-10 2022-01-13 Precigen, Inc. Fusion constructs and methods of using thereof
AU2021372815A1 (en) 2020-11-02 2023-06-22 Ares Trading S.A. Combination treatment of cancer
US20230372319A1 (en) 2020-11-02 2023-11-23 Ares Trading S.A. Combination Treatment of Cancer
WO2022105817A1 (en) * 2020-11-18 2022-05-27 Suzhou Transcenta Therapeutics Co., Ltd. Bi-functional molecules
JP2024517872A (ja) 2021-05-03 2024-04-23 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング ＨＥＲ２を標的にするＦｃ抗原結合性フラグメント－薬物抱合体
IL308818A (en) 2021-05-25 2024-01-01 Merck Patent Gmbh Egfr targeting fc antigen binding fragment-drug conjugates
EP4351640A1 (en) 2021-06-07 2024-04-17 Ares Trading S.A. Combination treatment of cancer

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017506217A (ja) 2014-02-10 2017-03-02 メルク パテント ゲーエムベーハー 標的ＴＧＦβ阻害

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4945050A (en) 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US5036006A (en) 1984-11-13 1991-07-30 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
KR970029803A (ko) 1995-11-03 1997-06-26 김광호 반도체 메모리장치의 프리차지 회로
WO2008106551A2 (en) 2007-02-28 2008-09-04 The Govt. Of The U.S.A. As Represented By The Secretary Of The Dept. Of Health & Human Serv. Brachyury polypeptides and methods for use
WO2014043518A1 (en) 2012-09-14 2014-03-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Brachyury protein, non-poxvirus non-yeast vectors encoding brachyury protein, and their use
WO2014043535A1 (en) 2012-09-14 2014-03-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compositions for the treatment of cancer
CN107428825A (zh) * 2014-10-10 2017-12-01 创祐生技股份有限公司 治疗及/或预防肿瘤生长、侵袭及/或转移的方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017506217A (ja) 2014-02-10 2017-03-02 メルク パテント ゲーエムベーハー 標的ＴＧＦβ阻害

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Increased expression of PDL1 by the human papillomavirus 16 E7 oncoprotein inhibits anticancer immunity，Mol Med Rep，2017年03月，Vol. 15, No. 3，p. 1063-1070，doi: 10.3892/mmr.2017.6102

Also Published As

Publication number Publication date
CA3063087A1 (en) 2018-11-15
US20200062849A1 (en) 2020-02-27
EP3624895A1 (en) 2020-03-25
WO2018208720A1 (en) 2018-11-15
US11440963B2 (en) 2022-09-13
AU2018266103B2 (en) 2024-06-13
JP2020519614A (ja) 2020-07-02
AU2018266103A1 (en) 2019-11-28
EP3624895B1 (en) 2025-12-10

Similar Documents

Publication Publication Date Title
JP7340458B2 (ja) Ｈｐｖ＋悪性腫瘍を有する患者におけるｐｄｌ１とｔｇｆベータの遮断の組み合わせ
JP6457003B2 (ja) 腫瘍溶解性ワクシニアウイルスの投与による腫瘍抗原に対する抗体の生成および腫瘍特異的補体依存性細胞傷害の生成
TWI823828B (zh) 免疫治療疫苗及抗體之組合治療
JP6747981B2 (ja) 腫瘍抗原発現組換えポックスウイルス及び免疫チェックポイント分子アンタゴニストまたはアゴニストを用いた癌治療のための併用療法
CN110678192B (zh) 溶瘤痘苗病毒与免疫检查点抑制剂联合疗法
JP6983819B2 (ja) 前立腺がん関連抗原を使用する腫瘍ワクチン接種用の組成物及び方法
JP7217936B2 (ja) 可溶性腫瘍壊死因子を阻害することによるがんの予防および治療
JP2016535989A (ja) 前立腺関連抗原を発現させるためのベクター
CN108136022A (zh) 使用b-raf抑制剂和免疫检查点抑制剂治疗癌症的方法
AU2021203071B2 (en) Treatment and functional cure of HIV infection by monoclonal antibodies to CD4 mediating competitive HIV entry inhibition
AU2021261676B2 (en) Method for treating cervical cancer
CN110831624A (zh) 涉及her抗原的用于肿瘤疫苗接种和免疫疗法的组合物及方法
US20200061167A1 (en) Combination of listeria-based vaccine with anti-ctla-4 or anti-cd137 antibodies
CN116723854A (zh) 肿瘤疫苗接种方法
CA3063087C (en) Combination pdl1 and tgf-beta blockade in patients with hpv+ malignancies
US20250188182A1 (en) Triple combination drug dosing therapy for head and neck cancer treatment
US20240115675A1 (en) Method of treating a tumor with a combination of an il-7 protein and a nucleotide vaccine
RU2741228C2 (ru) Противоопухолевые эффекты вирусного вектора, кодирующего толл-подобный рецептор и агонист толл-подобного рецептора
RU2832963C2 (ru) Способ лечения рака шейки матки
CN115025217B (zh) 干细胞裂解物联合活性多糖以及酪氨酸酶抑制剂在制备药物或化妆品中的用途
US20250127884A1 (en) Novel Epstein Barr Virus Immunotherapies

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210422

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210422

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220405

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220705

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20220705

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221115

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230214

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230515

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230801

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230828

R150 Certificate of patent or registration of utility model

Ref document number: 7340458

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150